Absorption, Stable Isotope Appearance and Non-transferrin-bound Iron (NTBI) Profile From NaFeEDTA and Ferrous Sulphate
SIA
1 other identifier
interventional
17
1 country
1
Brief Summary
Several iron compounds are used for fortification, including ferrous sulphate and NaFeEDTA. The absorption profile of these may differ because of differences in their dissolution in the gastrointestinal tract and in their interaction with dietary inhibitors of iron absorption. As these differences might lead result in varying reactions in the blood stream, the appearance rate of the stable iron isotope, hepcidin, non-transferrin-bound iron and total iron in the plasma will be monitored over six hours in adult women. This is relevant as a spike of absorbed iron may increase non-transferrin-bound iron and this could be pro-oxidative or increase growth of pathogens. Hepcidin is a key mediator of iron absorption and will help explain the potential differences in the plasma iron profile. The use of stable iron isotope appearance curves to specifically detect the appearance of small amounts of absorbed iron in the blood and distinguish between circulating body iron and iron absorbed from the test meal was tested in a pilot study (EK 2008-23). This method is now used in a bigger sample to test the differences in absorption profile of ferrous sulphate, FePPi and NaFeEDTA given at fortification level with a meal.
Trial Health
Trial Health Score
Automated assessment based on enrollment pace, timeline, and geographic reach
participants targeted
Target at below P25 for not_applicable
Started Jan 2010
Shorter than P25 for not_applicable
1 active site
Health score is calculated from publicly available data and should be used for screening purposes only.
Trial Relationships
Click on a node to explore related trials.
Study Timeline
Key milestones and dates
Study Start
First participant enrolled
January 1, 2010
CompletedFirst Submitted
Initial submission to the registry
January 20, 2010
CompletedFirst Posted
Study publicly available on registry
January 21, 2010
CompletedPrimary Completion
Last participant's last visit for primary outcome
March 1, 2010
CompletedStudy Completion
Last participant's last visit for all outcomes
March 1, 2010
CompletedApril 5, 2012
April 1, 2012
2 months
January 20, 2010
April 4, 2012
Conditions
Keywords
Outcome Measures
Primary Outcomes (1)
Stable iron isotope appearance in the plasma over 8 hours
day 1: 0', 30', 60', 120', 240', 480', day 8 0', 30', 60', 120', 240', 480'
Secondary Outcomes (1)
Isotope incorporation with erythrocytes
day 22
Study Arms (2)
NaFeEDTA
EXPERIMENTALThe maize porridge is fortified with 2.5mg iron as NaFeEDTA
FeSO4
ACTIVE COMPARATORThe maize porridge is fortified with 2.5 mg iron as ferrous sulphate plus ascorbic acid.
Interventions
265g maize porridge is fortified with 2.5 mg iron as NaFeEDTA.
Maize porridge is fortified with 2.5 mg iron as ferrous sulphate and 45 mg ascorbic acid.
Eligibility Criteria
You may qualify if:
- Serum ferritin \<60 ug/ l, haemoglobin \> 100 g/ l
- Women
- \< 65 kg body weight
- Healthy
You may not qualify if:
- Pregnant or lactating
- Taking iron supplements
Contact the study team to confirm eligibility.
Sponsors & Collaborators
Study Sites (1)
Laboratory of Human Nutrition
Zurich, Canton of Zurich, 08092, Switzerland
MeSH Terms
Conditions
Condition Hierarchy (Ancestors)
Study Design
- Study Type
- interventional
- Phase
- not applicable
- Allocation
- RANDOMIZED
- Masking
- SINGLE
- Who Masked
- PARTICIPANT
- Purpose
- PREVENTION
- Intervention Model
- CROSSOVER
- Sponsor Type
- OTHER
- Responsible Party
- PRINCIPAL INVESTIGATOR
- PI Title
- Prof
Study Record Dates
First Submitted
January 20, 2010
First Posted
January 21, 2010
Study Start
January 1, 2010
Primary Completion
March 1, 2010
Study Completion
March 1, 2010
Last Updated
April 5, 2012
Record last verified: 2012-04